Conversely, downregulation of DLC1 via genetic and epigenetic mechanisms occurs frequently in a variety of cancers, including liver cancer, lung cancer, colorectal cancer, prostate cancer, and breast cancer [26, 39–41]. Here, DLC1 is linked to cancer.